Skip to main content

Blog

PPMD Provides $250,000 in Funding to Secretome Therapeutics Through PPMD Venture Pathways Program to Support Development of Cardiac Cell Therapy

...

Sarepta Announces Plans to Submit sNDAs for AMONDYS 45 and VYONDYS 53

...

Sarepta Announces Initiation of Screening and Enrollment for ENDEAVOR Cohort 8 in Non-Ambulatory Individuals Living with Duchenne

...

Community Comes Together on Capitol Hill: A Recap of PPMD’s 2026 Advocacy Conference

...

Capricor Therapeutics Announces Positive Data from HOPE-3 Study of Deramiocel

...

Solid Biosciences Shares Interim Positive Update on Phase 1/2 INSPIRE DUCHENNE Trial

...

REGENXBIO Shares Positive Interim Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202

...

Edgewise Announces Positive Long-Term Sevasemten Data

...

Capricor Therapeutics Announces New PDUFA Date for Deramiocel

...

PPMD and FED Announce 2026 Advocacy Leadership Awards Honoring Bipartisan Champions in Congress

...